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of toxicity in conjunction with pharmacogenomics, 
validating imaging as early indicator of efficacy, and 
evaluation of the use of serial biopsies especially at 
clinical or radiographic progression. For proposal 
evaluation, the panel would consider 3 key features: 
the novelty and feasibility of proposal, clinical relevant 
endpoints and robust statistics, and promising predictive 
biomarker and properly validated assays.
The discussion of 2 adjuvant trials proposed by 
ECOG-ACRIN and Alliance for the study of ALK 
rearrangement/crizotinib and EGFR mutations/erlotinib, 
respectively, resulted in the design of ALCHEMIST 
(Adjuvant Lung Cancer Enrichment Marker 
Identification and Sequencing Trial). Patients with 
resectable (stage IB, II, and IIIA) lung adenocarcinoma 
will be screened for EGFR mutations and ALK fusion 
under an umbrella screening protocol, and then assigned 
to separate adjuvant studies comparing erlotinib addition 
or crizotinib addition, respectively, with placebo. Overall 
survival is the primary endpoint. Also as a result of this 
workshop, the NCI “Master Protocol” phase II/III trial 
for second-line treatment of squamous lung cancer (the 
LungMAP trial) was developed. Patients will be screened 
by a Next-Generation DNA Sequencing mutation panel 
and immunohistochemistry assays for specific genetic 
alterations, and then randomized to standard or new 
targeted therapy. Those without the biomarkers will be 
randomized to immunotherapy versus chemotherapy. 
Progression-free survival is the primary endpoint.
The Master Protocols are developed to expedite the 
generation of evidence-based efficacy of new therapies 
leading to FDA approval and ultimately improved 
patient outcomes. (p. 1443)
•	 Resource Utilization and 
Costs during the Initial 
Years of Lung Cancer 
Screening with Computed 
Tomography in Canada
This is the first prospective analysis of data on resource 
utilization and costs for critical information to guide the 
decision on the implementation of low-dose computed 
tomography (LDCT) lung cancer screening programs. 
In the Pan-Canadian Early Detection of Lung Cancer 
Study using LDCT, 2,059 participants from 7 major 
Canadian cities with ≥ 2% lung cancer risk over 3 years 
were enrolled, and from which resource utilization data 
were prospectively collected. The Canadian public payer’s 
view on resources used for the screening and treatment 
in the initial years were assessed in the cost analysis. 
The findings revealed that whereas screening costs 
strongly varied with lung nodule size, presence of cancer, 
screening intervention and the screening center, the initial 
18-months of LDCT after a baseline scan generated an 
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Experts from academia, clinical research, industry and government 
met at a joint workshop of the NCI Thoracic Malignancies 
Steering Committee and the FDA with the aims of achieving initial 
consensus on a high priority biomarker-driven trial to accelerate 
assessment and approval of targeted agents for molecularly 
defined lung cancer subsets, and determining the challenges for 
such trial and strategies to address these challenges. This report 
covers trial design issues including biomarker incorporation 
and relevant endpoints, regulatory challenges such as different 
requirement for US and EU accelerated/conditional approval and 
companion diagnostics development costs, efforts in drug, and 
biomarker codevelopment such as validated multiplex assays 
for FDA approval. Learning from past experiences, the panel 
agreed that a promising biomarker is needed to further large trials 
with angiogenic agents in NSCLC (Bevacizumab in phase III 
E4599), standardized specimen acquisition and storage practices 
are necessary (BATTLE), and to include patients negative for 
biomarkers in a concurrent trial of nontargeted agent, for instance. 
For future lung cancer trial development, the panel overall agreed 
on integrating validated biomarkers in trial designs, assessment 
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•	 Comprehensive Molecular 
Profiling of Lung 
Adenocarcinoma
76% of the samples, therefore expanding potential 
therapeutic targets within this pathway. The discovery 
of the loss-of-function MGA mutations also highlighted 
the role of MYC pathway in lung adenocarcinoma. 
Furthermore, chromatin modifications and splicing 
alterations were identified, for instance exon 14 
skipping in MET that leads to its activation, somatic 
mutation associated with CDKN2A methylation in a 
subset of CIMP-H tumors. Taken together, this study 
provided new insights on novel genetic alterations 
in a well-known cancer-causing pathway in lung 
adenocarcinomas, potentially increasing actionable 
targets that would help match patients to an optimal 
targeted therapy.
The Cancer Genome Atlas Research, N. Comprehensive 
molecular profiling of lung adenocarcinoma. Nature 
2014;511:543–550, doi:10.1038/nature13385. Available 
at: http://www.nature.com/nature/journal/v511/n7511/abs/
nature13385.html#supplementary-information.
ethnic minority status, and treatment setting (public or 
tertiary care center). They utilized the Beck Depression 
Inventory-II (BDI-II) to examine patients for depressed 
mood at baseline, at approximately 6, 12, and 18 weeks. 
Increased depressive severity was found in patients with 
less versus more education whereas treatment setting 
and minority status did not affect depressive severity. No 
significant interaction was observed between education 
level and treatment setting. Taken together, these 
findings underscored the presence of SES differences 
in depressive severity in this patient population, 
independent of minority status and the hospital context 
where they received treatment. (p. 1459)
•	 Socioeconomic Status 
Is Associated with 
Depressive Severity among 
Patients with Advanced 
Non-Small Cell Lung 
Cancer: Treatment Setting 
and Minority Status Do 
Not Make a Difference
Fagundes et al. investigated the association between depressive 
severity in non-small cell lung cancer (NSCLC) patients and 
individual socioeconomic status (SES; by level of education), racial/
average cost per person of $453. They also found that the 
average cost per person treating lung cancer with curative 
surgery was lower than that of treating advanced lung 
cancer with chemotherapy, radiotherapy or supportive care 
alone ($33,344 versus $47,792; p = 0.061). All in all, this 
study indicated lower average costs using LDCT to screen 
high risk individuals and in curative treatment compared 
with that in advanced stage lung cancer treatments. These 
findings could be valuable to inform program evaluation 
and future cost-effectiveness models. (p. 1449)
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The Cancer Genome Atlas Research Network research team, 
led by Matthew Meyerson, analyzed the mutation profiles, 
structural rearrangements, copy number alterations, DNA 
methylation, mRNA, miRNA and protein expression of 230 lung 
adenocarcinomas. They identified 18 statistically significant genetic 
mutations, including novel alterations such as NF1 and RIT1 
mutations, and amplifications in MET and ERBB2. Abnormalities 
in NF1, MET, ERBB2, and RIT1 were found in 13% of the samples, 
especially in oncogene-negative lung adenocarcinomas, suggesting 
their driver roles in these tumors. The findings demonstrated that 
genetic alterations of the RTK/RAS/RAF pathway accounted for 
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was significantly associated with positive skewness (a 
measure of asymmetry of the histogram; p = 0.031) and 
lower kurtosis (a measure of peakedness and tailedness; 
p = 0.009). A 5 node decision tree from the Monte Carol 
analysis showed 96.3% of sensitivity, 81.0% of specificity, 
and 89.6% of accuracy. Tumor heterogeneity information 
such as kurtosis was significantly associated with overall 
survival (OS) and disease-free survival (DFS); lower 
kurtosis value correlated with poorer OS (p = 0.048), and 
shorter DFS (p = 0.049). This new noninvasive imaging 
approach could differentiate KRAS mutation from pan-
wild-type NSCLC tumors and could be prognostic for OS 
and DFS in NSCLC patients. Validation of these findings 
in independent NSCLC sample sets is warranted.
Weiss GJ, Ganeshan B, Miles KA, et al. Noninvasive 
image texture analysis differentiates K-ras mutation from 
pan-wildtype NSCLC and is prognostic. PLoS ONE 
2014;9:e100244, doi:10.1371/journal.pone.0100244.
•	 Dual Inhibition of 
EGFR with Afatinib and 
Cetuximab in Kinase 
Inhibitor-Resistant EGFR-
Mutant Lung Cancer 
with and without T790M 
Mutations
and T790M-negative tumors (32% versus 25%; p = 
0.341). The overall median duration of responses was 5.7 
months, and the median progression-free survival was 
4.7 months. Grade 3/4 toxicities were treatment-related 
and manageable. The findings provided the first clinical 
confirmation of the preclinical hypothesis that a significant 
proportion of EGFR-mutant lung adenocarcinomas with 
acquired resistance to erlotinib and gefitinib are still 
dependent on EGFR signaling for growth and survival. 
The results demonstrated promising clinical efficacy of 
the afatinib and cetuximab combination with manageable 
safety profile, which warrants further investigations.
Janjigian YY, Smit EF, Groen HJ, et al. Dual 
inhibition of EGFR with Afatinib and Cetuximab in 
Kinase Inhibitor-Resistant EGFR-Mutant Lung Cancer 
with and without T790M Mutations. Cancer Discov 
2014, doi:10.1158/2159–8290.cd-14–0326.
•	 Noninvasive Image Texture 
Analysis May Provide Tumor 
Heterogeneity Information 
with Prognostic Potential in 
NSCLC
This study assessed the use of quantitative computed tomography 
(CT) based texture analysis (QTA) in differentiating the presence 
of KRAS mutation from pan-wild-type non-small cell lung cancer 
(NSCLC), and its prognostic value in baseline pretreatment 
noncontrast CT imaging in NSCLC. Formalin-fixed, paraffin-
embedded, early-stage NSCLC tumor tissues (n = 48) were analyzed 
on the LungCarta Panel for 26 oncogenes and tumor-suppressor 
genes (AKT1, ALK, BRAF, DDR2, EGFR, EPHA3, EPHA5, 
ERBB2, FGFR4, JAK2, KRAS, MAP2K1, STK11, MET, NOTCH1, 
NRAS, NRF2, NTRK1, NTRK2, NTRK3, PIK3CA, PTCH1, PTEN, 
PTPN11, PTPRD, and TP53). QTA identified 27 KRAS mutant 
and 21 pan-wild-type tumors. The presence of a KRAS mutation 
Based on the preclinical findings that showed the combination of 
afatinib (irreversible ErbB family blocker) and cetuximab (anti-EGFR 
monoclonal antibody) overcame T790M-mediated resistance, a phase 
Ib study conducted by Janjigian et al. investigated this combination 
in patients with advanced EGFR-mutant lung cancer and acquired 
resistance to erlotinib/gefitinib in the Netherlands and the US. Post-
acquired-resistance tumor samples from patients were collected for 
EGFR mutation testing. Of the 126 patients receiving the combination, 
an overall objective response rate of 29% was observed, and was 
not significantly different between patients with T790M-positive 
•	 Electronic Cigarettes: 
Review of Use, Content, 
Safety, Effects on Smokers 
and Potential for Harm 
and Benefit
Hajek and colleagues reviewed studies on electronic cigarettes (EC) 
up to February 2014 to obtain data on their use, content and safety in 
order to examine the potential harm and benefit of EC. The findings 
would potentially set guidelines for future policy and regulations. 
Their review demonstrated that, when comparing with tobacco 
smoke, EC produce aerosol with lower levels of toxic chemicals, and 
they could pose much less harm to users or bystanders, despite its 
unknown long-term effects on health. The authors did not observe 
any regular EC use in never-smokers or nonsmoking 
children, despite its popularity among smokers, some 
of whom reduced or quit smoking through EC. The 
authors concluded that current evidence suggest potential 
benefits of EC as a substitute of tobacco cigarettes 
in the market, which might reduce smoking-related 
morbidity and mortality, and as a potentially invaluable 
tool in smoking cessation. They also advised against 
strict regulations on EC similar to or more than those on 
conventional cigarettes.
Hajek P, Etter J-F, Benowitz N, Eissenberg T, 
McRobbie H. Electronic cigarettes: review of use, 
content, safety, effects on smokers and potential for harm 
and benefit. Addiction 2014, doi:10.1111/add.12659.
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dual use of e-cigarettes with conventional cigarettes, 
no proven benefits on cessation, and increasing youth 
initiation with e-cigarettes (one-third of which have 
never been a conventional cigarette smoker). In light of 
data showing e-cigarettes emit lower levels of chemical 
toxins than those in cigarette smoke, the potential of 
e-cigarette use in place of cigarette smoking to reduce 
the harm caused by the latter raises concerns, as a result 
of e-cigarette effects on youth, dual use with cigarettes 
causing delayed cessation, and renormalization 
of smoking behavior. The authors concluded that 
e-cigarette use should be subject to marketing 
restrictions and prohibition as in the use of tobacco 
cigarette, such as 100% smoke-free policy.
Grana R, Benowitz N, Glantz SA. E-cigarettes: a 
scientific review. Circulation 2014;129:1972–1986.
NEWS IN BRIEF
•	 National Clinical Trials 
Network Launched Lung-
MAP for Personalized 
Medicine
Foundation Medicine joined forces on the Lung 
Cancer Master Protocol (Lung-MAP) trial for patients 
with advanced squamous cell lung cancer. The trial 
allows patients to be tested for multiple biomarkers 
simultaneously using genomic profiling and assigns 
them to 1 of the 5 trial arms that is best matched to 
their tumor genomic profiles. Five experimental drugs 
(4 targeted agents and an anti-PD-L1 immunotherapy) 
will be tested initially under 1 master protocol, which 
can be amended as needed, preserving infrastructure 
and patient outreach efforts. Between 500 and 1,000 
patients are anticipated to be screened per year for 
> 200 genomic abnormalities in cancer at over 200 
medical centers. Five to seven additional drugs could 
be tested over the next 5 years, costing up to $160 
million. This multi-drug, multi-arm, biomarker driven 
clinical study will provide patients with better access to 
optimal therapies and reduce burdens on researchers in 
traditional clinical trials.
•	 E-Cigarettes: A Scientific 
Review
Grana et al. conducted a systematic review of a total of 82 articles 
with original data obtained from literature searches via PubMed, 
World Health Organization and other relevant sources. They 
analyzed data on e-cigarette liquid and aerosol contents, prevalence, 
secondhand exposure, its effects on health and conventional 
cigarette cessation, tobacco industry marketing and media research, 
the current global regulations, and policy recommendations. Based 
on limited current evidence, this review indicated high rates of 
As part of the program from the National Clinical Trials Network, 
the National Cancer Institute (NCI), SWOG Cancer Research, 
Friends of Cancer Research, the Foundation for the National 
Institutes of Health (FNIH), 5 pharmaceutical companies, and 
•	 AstraZeneca Partners 
with Roche and Qiagen 
for New Blood-Based 
Companion Tests for Lung 
Cancer Treatment
AstraZeneca has teamed up with Roche and Qiagen to 
develop diagnostic tests that would identify non-small 
cell lung cancer (NSCLC) patients with specific genetic 
mutations, who might benefit from its lung cancer drugs. 
The new tests detect EGFR mutations from circulating 
tumor DNA in the plasma collected from the patients. 
Qiagen will develop such test to guide treatments with 
gefitinib in NSCLC patients. Roche on the other hand 
will develop such test for the development of AZD9291 
for NSCLC patients resistant to first generation tyrosine 
kinase inhibitors.
Image credit: CDC
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The launch of a multi-center, international perspective 
study, the Genomics of Young Lung Cancer under the joined 
forces of Foundation Medicine, the Addario Lung Cancer 
Medical Institute (ALCMI) and Bonnie J. Addario Lung 
Cancer Foundation (ALCF) aims to find better treatments 
for young adults with lung cancer and tailor therapies to 
them. Of the 224,000 new lung cancer diagnosis expected 
this year, 3,700 will be in patients under age 45. These young 
adults exhibit distinct manner of lung cancer, usually without 
typical symptoms and signs of the disease. This study, 
employing the validated comprehensive genomic profile 
FoundationOne®, would identify novel genetic drivers of 
lung cancers unique to these underserved patients, and match 
them with relevant targeted therapies and clinical trials.
electronic_cigarettes_many_questions_still_limited_
research-1420). Another article published in Circulation 
(Circulation, doi:10.1161/circulationaha.114.007667) 
comes to some opposing conclusions and interestingly, 
shares a co-author with the Addiction article. The 
Circulation article reviewed 71 articles retrieved from 
PubMed and provides an appealingly encyclopaedic 
approach to e-cigarettes including graphics of various 
types of e-cigarettes (disposable, rechargable, “pen-style”) 
and a discussion of the components of the vapor including 
particulate matter and references to some possibly 
fascinating studies of the cytotoxicity of e-cigarette vapor, 
the translation of which to clinical effects is unclear. What 
is clear however is the controversy over e-cigarettes; a 
short time searching the Internet can quickly identifying 
multiple headlines from both sides of the argument.
What is less controversial is a decline in smoking rates 
in Australia (a country where e-cigs are banned) between 
2010 and 2013, reported by the Australian Institute of 
Health and Welfare, a government body that provides 
regular statistical reporting on health issues. The Institute 
reports in the 2013 National Drugs Strategy Household 
Survey that daily smoking in Australia has fallen from 
15.1% in 2010 to 12.8% in 2013 with a reduction 
in uptake in smoking by young people. The Sydney 
Morning Herald (web reference below) links this decline 
to the introduction of Australia’s plain packaging laws, 
passed in parliament in 2011.
Available at: http://www.aihw.gov.au/alcohol-and- 
other-drugs/ndshs/; 
Available at: http://www.smh.com.au/federal-politics/ 
political-news/plunge-in-smoking-attributed-to-plain-
packaging-20140716-ztqht.html.
And in more plain packaging news, South Africa is 
planning to introduce this in 2015 reports Reuters (web 
reference below). This adds South Africa to the growing 
list of countries considering plain packaging.
Available at: http://www.reuters.com/article/2014/07/24/
us-safrica-tobacco-idUKKBN0FT1QI20140724?irpc=932.
•	 Innovative Prospective 
Study in Young Adults 
with Lung Cancer to Find 
Genomic Changes for 
Tailored Therapies
Image credit: Mike Blackburn. Available 
at: http://www.flickr.com/photos/
mikeblackburn/5520196331/.
•	 News by the IASLC 
Tobacco Control 
Committee
More confusing information about e-cigarettes continues to make 
headlines. E-cigarettes “less harmful” than cigarettes heads a BBC 
report (Available at: http://www.bbc.com/news/health-28554456) 
which examines a article recently published in Addiction. The 
report provides a cartoon image of e-cigarette anatomy (Addiction, 
doi:10.1111/add.12659) and highlights tensions in the e-cig debate. 
The conclusions identified in the report suggest that “switching 
to e-cigarettes can reduce cigarette consumption” and quotes 1 
of the authors, Professor Peter Hajek, warning against a failure 
to “give smokers access to these safer products that could save 
their lives. The article itself reviews 81 articles identified in major 
health databases and concluded that e-cigarettes had a number 
of hypothetical disadvantages (toxin levels, combined use with 
conventional cigarettes, penetration of the youth market, increase in 
smoking prevalence) and 1 hypothetical advantage (the reduction 
in conventional cigarette use) none of which had been conclusively 
demonstrated. Other news outlets reporting e-cigarettes as a cessation 
strategy deserving support include The Times (Available at: http://
www.thetimes.co.uk/tto/health/news/article4162503.ece?CMP=OTH-
gnws-standard-2014_07_30) and the online science blog 
Science2.0 (Available at: http://www.science20.com/news_articles/
Image credit: WHO
